Literature DB >> 11739180

Asymptomatic primary Epstein-Barr virus infection occurs in the absence of blood T-cell repertoire perturbations despite high levels of systemic viral load.

S L Silins1, M A Sherritt, J M Silleri, S M Cross, S L Elliott, M Bharadwaj, T T Le, L E Morrison, R Khanna, D J Moss, A Suhrbier, I S Misko.   

Abstract

Primary infection with the human herpesvirus, Epstein-Barr virus (EBV), may result in subclinical seroconversion or may appear as infectious mononucleosis (IM), a lymphoproliferative disease of variable severity. Why primary infection manifests differently between patients is unknown, and, given the difficulties in identifying donors undergoing silent seroconversion, little information has been reported. However, a longstanding assumption has been held that IM represents an exaggerated form of the virologic and immunologic events of asymptomatic infection. T-cell receptor (TCR) repertoires of a unique cohort of subclinically infected patients undergoing silent infection were studied, and the results highlight a fundamental difference between the 2 forms of infection. In contrast to the massive T-cell expansions mobilized during the acute symptomatic phase of IM, asymptomatic donors largely maintain homeostatic T-cell control and peripheral blood repertoire diversity. This disparity cannot simply be linked to severity or spread of the infection because high levels of EBV DNA were found in the blood from both types of acute infection. The results suggest that large expansions of T cells within the blood during IM may not always be associated with the control of primary EBV infection and that they may represent an overreaction that exacerbates disease.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11739180     DOI: 10.1182/blood.v98.13.3739

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

Review 1.  Heterologous immunity between viruses.

Authors:  Raymond M Welsh; Jenny W Che; Michael A Brehm; Liisa K Selin
Journal:  Immunol Rev       Date:  2010-05       Impact factor: 12.988

2.  On the dynamics of acute EBV infection and the pathogenesis of infectious mononucleosis.

Authors:  Vey Hadinoto; Michael Shapiro; Thomas C Greenough; John L Sullivan; Katherine Luzuriaga; David A Thorley-Lawson
Journal:  Blood       Date:  2007-11-08       Impact factor: 22.113

3.  Cross-reactive influenza virus-specific CD8+ T cells contribute to lymphoproliferation in Epstein-Barr virus-associated infectious mononucleosis.

Authors:  Shalyn C Clute; Levi B Watkin; Markus Cornberg; Yuri N Naumov; John L Sullivan; Katherine Luzuriaga; Raymond M Welsh; Liisa K Selin
Journal:  J Clin Invest       Date:  2005-11-23       Impact factor: 14.808

4.  The interplay between local immune response and Epstein-Barr virus-infected tonsillar cells could lead to viral infection control.

Authors:  Aldana G Vistarop; Melina Cohen; Fuad Huaman; Lucia Irazu; Marcelo Rodriguez; Elena De Matteo; María Victoria Preciado; Paola A Chabay
Journal:  Med Microbiol Immunol       Date:  2018-07-25       Impact factor: 3.402

5.  Comparison of quantitative competitive PCR with LightCycler-based PCR for measuring Epstein-Barr virus DNA load in clinical specimens.

Authors:  Servi J C Stevens; Sandra A W M Verkuijlen; Adriaan J C van den Brule; Jaap M Middeldorp
Journal:  J Clin Microbiol       Date:  2002-11       Impact factor: 5.948

6.  Plasmodium falciparum infection is associated with Epstein-Barr virus reactivation in pregnant women living in malaria holoendemic area of Western Kenya.

Authors:  Ibrahim I Daud; Sidney Ogolla; Asito S Amolo; Eunice Namuyenga; Kenneth Simbiri; Elizabeth A Bukusi; Zipporah W Ng'ang'a; Robert Ploutz-Snyder; Peter O Sumba; Arlene Dent; Rosemary Rochford
Journal:  Matern Child Health J       Date:  2015-03

Review 7.  Progress and problems in understanding and managing primary Epstein-Barr virus infections.

Authors:  Oludare A Odumade; Kristin A Hogquist; Henry H Balfour
Journal:  Clin Microbiol Rev       Date:  2011-01       Impact factor: 26.132

Review 8.  Heterologous immunity: immunopathology, autoimmunity and protection during viral infections.

Authors:  Liisa K Selin; Myriam F Wlodarczyk; Anke R Kraft; Siwei Nie; Laurie L Kenney; Roberto Puzone; Franco Celada
Journal:  Autoimmunity       Date:  2011-01-20       Impact factor: 2.815

9.  Epstein-Barr virus-associated lymphoproliferative disease in non-immunocompromised hosts: a status report and summary of an international meeting, 8-9 September 2008.

Authors:  J I Cohen; H Kimura; S Nakamura; Y-H Ko; E S Jaffe
Journal:  Ann Oncol       Date:  2009-06-10       Impact factor: 32.976

10.  Phase I trial of a CD8+ T-cell peptide epitope-based vaccine for infectious mononucleosis.

Authors:  Suzanne L Elliott; Andreas Suhrbier; John J Miles; Greg Lawrence; Stephanie J Pye; Thuy T Le; Andrew Rosenstengel; Tam Nguyen; Anthony Allworth; Scott R Burrows; John Cox; David Pye; Denis J Moss; Mandvi Bharadwaj
Journal:  J Virol       Date:  2007-11-21       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.